Abstract is: Alan Ashworth, FRS (born 1960 in Bolton, Lancashire) is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research (ICR) in London.
| human | Q5 |
| P2070 | Fellow of the Royal Society ID | 11011 |
| P646 | Freebase ID | /m/0b6gz_4 |
| P496 | ORCID iD | 0000-0003-1446-7878 |
| P10897 | ORKG ID | R55336 |
| P3368 | Prabook ID | 2553547 |
| P1153 | Scopus author ID | 35379025100 |
| P6424 | affiliation string | Breakthrough Breast Cancer Research Centre | |
| P166 | award received | Meyenburg Prize | Q1926301 |
| Fellow of the AACR Academy | Q61636373 | ||
| Fellow of the Royal Society | Q15631401 | ||
| P27 | country of citizenship | United Kingdom | Q145 |
| P185 | doctoral student | Elizabeth Iorns | Q5363014 |
| P69 | educated at | University College London | Q193196 |
| P108 | employer | University of California, San Francisco | Q1061104 |
| Institute of Cancer Research | Q6039999 | ||
| P734 | family name | Ashworth | Q37541102 |
| Ashworth | Q37541102 | ||
| Ashworth | Q37541102 | ||
| P735 | given name | Alan | Q294833 |
| Alan | Q294833 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P463 | member of | Royal Society | Q123885 |
| P106 | occupation | biochemist | Q2919046 |
| P1344 | participant in | World Economic Forum Annual Meeting 2004 | Q114717220 |
| P21 | sex or gender | male | Q6581097 |
| P6886 | writing language | English | Q1860 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q24336639 | 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q48195931 | A candidate spermatogenesis gene on the mouse Y chromosome is homologous to ubiquitin-activating enzyme E1 |
| Q33294239 | A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D. |
| Q24321364 | A conserved family of genes related to the testis determining gene, SRY |
| Q41943655 | A distinct spectrum of copy number aberrations in pediatric high-grade gliomas |
| Q36634679 | A gene spans the pseudoautosomal boundary in mice |
| Q28487036 | A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity |
| Q28943455 | A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3) |
| Q36682471 | A genome-wide association study of early menopause and the combined impact of identified variants |
| Q39890862 | A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines |
| Q39112227 | A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q36204215 | A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer |
| Q34467375 | A missense mutation in the BRCA2 gene in three siblings with ovarian cancer |
| Q30469740 | A modified method for whole exome resequencing from minimal amounts of starting DNA |
| Q42506542 | A mouse model of basal-like breast carcinoma with metaplastic elements |
| Q57272218 | A new gene on the X involved in Fanconi anemia |
| Q60907584 | A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors |
| Q55561844 | A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations. |
| Q41063635 | A role for JNK/SAPK in proliferation, but not apoptosis, of IL-3-dependent cells |
| Q38279200 | A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor |
| Q41007686 | A targeted deletion in the endocytic receptor gene Endo180 results in a defect in collagen uptake |
| Q37158337 | A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers |
| Q48204757 | A zinc finger protein-encoding gene expressed in the post-meiotic phase of spermatogenesis |
| Q24304176 | APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer |
| Q37508792 | ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. |
| Q54494486 | AXL and acquired resistance to EGFR inhibitors. |
| Q64388767 | Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification |
| Q61867696 | Abstract 2931: Cancer cells deficient in DNA mismatch repair (MMR) are selectively sensitive to inhibition of the DNA dependent protein kinase (DNA-PK) |
| Q63383804 | Abstract 3417: An in vivo functional screen to identify metastasis suppressor genes |
| Q61867999 | Abstract 350: High-throughput drug screens identify novel synthetic lethal interactions with MLH1-deficient cancers |
| Q63383808 | Abstract 3917: EMSY amplification and overexpression is not associated with defective homologous recombination and does not predict sensitivity to cisplatin or PARP inhibitors |
| Q63383817 | Abstract 4829: Massively parallel RNA sequencing analysis of micropapillary carcinomas of the breast |
| Q63383816 | Abstract 4987: Identification of novel genes and pathways involved in resistance to HER2-targeting agents in breast cancer |
| Q63383801 | Abstract A09: Induced aggravation of oxidative DNA damage as a targeted synthetic lethal approach in mismatch repair-deficient tumors |
| Q63383800 | Abstract A36: A transposon-based genetic screen in haploid mouse embryonic stem cells identifies Parp1 as a major mediator of olaparib toxicity |
| Q57319547 | Abstract P3-08-04: Impact of CYP3A variation on estrone levels and breast cancer risk |
| Q63383805 | Abstract PD05-08: Genomic characterisation of invasive breast cancers with heterogeneous HER2 gene amplification |
| Q63383803 | Abstract S4-02: Integrated genomic analyses of members of protein kinase C family identifies subtype specific alterations as novel therapeutic targets |
| Q57199717 | Abstracts |
| Q58421479 | Abstracts from the 2011 BNOS Conference, June 29 - July 1, 2011, Homerton College, Cambridge |
| Q47915665 | Alternative splicing of the Drosophila PTEN gene |
| Q33955851 | An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence |
| Q28769978 | An SRY-related gene expressed during spermatogenesis in the mouse encodes a sequence-specific DNA-binding protein |
| Q39024676 | An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor |
| Q41323436 | An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cells |
| Q42458622 | An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers |
| Q37676107 | An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer |
| Q40224466 | Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors |
| Q24683771 | Analysis of PALB2/FANCN-associated breast cancer families |
| Q40307663 | Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss |
| Q38440321 | Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. |
| Q43608304 | Association of genetic variants at 8q24 with breast cancer risk |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q36039180 | Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition |
| Q74310874 | BRCA1 and BRCA2 |
| Q42476392 | BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells |
| Q42502209 | BRCA1 dysfunction in sporadic basal-like breast cancer |
| Q34381053 | BRCA2 mutations in primary breast and ovarian cancers |
| Q40357640 | BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency |
| Q38699280 | BRCAness revisited |
| Q35770209 | Basal-like breast carcinomas: clinical outcome and response to chemotherapy |
| Q33552888 | Biology-driven cancer drug development: back to the future |
| Q74302484 | Biomedicine. D-Day for BRCA2 |
| Q43581448 | Body mass index, exercise, and other lifestyle factors in relation to age at natural menopause: analyses from the breakthrough generations study |
| Q27347240 | Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis |
| Q42467730 | Breast cancer molecular profiling with single sample predictors: a retrospective analysis |
| Q62583508 | Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study |
| Q39850364 | Bringing DNA repair in tumors into focus |
| Q34480618 | CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells |
| Q27853338 | CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours |
| Q24320073 | CRK7 modifies the MAPK pathway and influences the response to endocrine therapy |
| Q28201693 | CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members |
| Q44288178 | CYP3A variation, premenopausal estrone levels, and breast cancer risk |
| Q41739799 | Cancer predisposition: where's the phosphate? |
| Q40187957 | Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis |
| Q40644286 | Cell cycle and genetic background dependence of the effect of loss of BRCA2 on ionizing radiation sensitivity |
| Q45233639 | Challenges translating breast cancer gene signatures into the clinic |
| Q50999553 | Changes in estradiol and testosterone levels in postmenopausal women after changes in body mass index. |
| Q33579776 | Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast |
| Q37630918 | Childhood body size and pubertal timing in relation to adult mammographic density phenotype |
| Q24313653 | Chromosomal localization of three human dual specificity phosphatase genes (DUSP4, DUSP6, and DUSP7) |
| Q34419177 | Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene |
| Q37681743 | Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study |
| Q34399372 | Common genetic variants are significant risk factors for early menopause: results from the Breakthrough Generations Study |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q49997179 | Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q27853152 | Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity |
| Q33959327 | Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer |
| Q53307462 | Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation. |
| Q72966127 | Control of aromatase in breast cancer cells and its importance for tumor growth |
| Q89662330 | Correction to: Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study |
| Q42360725 | Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours |
| Q42876061 | Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q58549299 | Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours |
| Q57319824 | Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility |
| Q36195450 | Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib |
| Q36696957 | Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer |
| Q34567112 | Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress |
| Q45250824 | DAISY: picking synthetic lethals from cancer genomes |
| Q37763102 | DNA amplifications in breast cancer: genotypic-phenotypic correlations |
| Q24562937 | DNA binding and bending properties of the post-meiotically expressed Sry-related protein Sox-5 |
| Q33754229 | DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1 |
| Q37110904 | DNA repair deficiency as a therapeutic target in cancer |
| Q49981106 | DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. |
| Q28586983 | DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells |
| Q125896798 | De novo design of drug-binding proteins with predictable binding energy and specificity |
| Q64388338 | Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition |
| Q36248613 | Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. |
| Q33841869 | Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction |
| Q60601757 | Design and discovery of 3-aryl-5-substituted-isoquinolin-1-ones as potent tankyrase inhibitors |
| Q24633288 | Determinants of age at menarche in the UK: analyses from the Breakthrough Generations Study |
| Q40738790 | Differential effects of stress stimuli on a JNK-inactivating phosphatase |
| Q24338293 | Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways |
| Q28201328 | Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1 |
| Q22242910 | Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiation |
| Q39964619 | Dissecting resistance to endocrine therapy in breast cancer |
| Q36117022 | Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland |
| Q42489677 | Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue |
| Q43294276 | Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis |
| Q47642032 | Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study |
| Q38962047 | Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling |
| Q51974206 | Dynamic expression of Erbb pathway members during early mammary gland morphogenesis. |
| Q38493679 | Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours |
| Q38127164 | Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study |
| Q38702556 | Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells |
| Q37827340 | Emerging therapeutic targets in endometrial cancer |
| Q35914867 | Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis |
| Q24795234 | Erratum to: Functional and molecular characterisation of mammary side population cells |
| Q59041387 | Erratum: Identification of the breast cancer susceptibility gene BRCA2 |
| Q34256029 | Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation |
| Q24684071 | Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data |
| Q51773510 | Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation. |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q47923860 | Evolutionary rate of a gene affected by chromosomal position |
| Q36196882 | Exome Sequencing of an Adult Pituitary Atypical Teratoid Rhabdoid Tumor |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q36204224 | FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo |
| Q27851554 | FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer |
| Q40205335 | FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas |
| Q57319538 | FGFR2 genotype and risk of radiation-associated breast cancer in Hodgkin lymphoma |
| Q33887367 | FXY2/MID2, a gene related to the X-linked Opitz syndrome gene FXY/MID1, maps to Xq22 and encodes a FNIII domain-containing protein that associates with microtubules. |
| Q42596418 | Familial concordance for age at menarche: analyses from the Breakthrough Generations Study |
| Q42598119 | Familial concordance for age at natural menopause: results from the Breakthrough Generations Study |
| Q44611248 | Familial concordance for height and its components: analyses from the Breakthrough Generations Study |
| Q38746332 | Family history and risk of breast cancer: an analysis accounting for family structure |
| Q37307305 | Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q39342402 | Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. |
| Q103837502 | Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking |
| Q71468740 | Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia |
| Q40083916 | Functional analysis of Drosophila melanogaster BRCA2 in DNA repair |
| Q24794990 | Functional and molecular characterisation of mammary side population cells |
| Q39511351 | Functional characterization of EMSY gene amplification in human cancers |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q35281860 | Functional viability profiles of breast cancer |
| Q43682274 | Gene expression following ionising radiation: identification of biomarkers for dose estimation and prediction of individual response |
| Q46831638 | Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance |
| Q29417068 | Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q34031201 | Genetic variants at chromosomes 2q35, 5p12, 6q25.1, 10q26.13, and 16q12.1 influence the risk of breast cancer in men |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q36180219 | Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal differentiation |
| Q55230708 | Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q29417050 | Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk |
| Q36293767 | Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells |
| Q35779181 | Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen |
| Q27852678 | Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity |
| Q40380087 | Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH. |
| Q33475741 | Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation |
| Q35812762 | Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers |
| Q58593960 | Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer |
| Q62746983 | Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer |
| Q34760593 | Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines |
| Q42471198 | Genomic and immunohistochemical analysis of adenosquamous carcinoma of the breast |
| Q39349974 | Genomic characterisation of acral melanoma cell lines |
| Q37627703 | Genomic instability and the selection of treatments for cancer |
| Q28245028 | Germline mutations in RAD51D confer susceptibility to ovarian cancer |
| Q35789595 | Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q34054107 | High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing |
| Q24300843 | High-throughput RNAi screening reveals novel regulators of telomerase |
| Q39173934 | Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. |
| Q51925106 | IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q24309649 | Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer |
| Q34212750 | Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma |
| Q34060031 | Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines |
| Q58290724 | Identification of genetic variants that influence circulating IGF1 levels: a targeted search strategy |
| Q44445186 | Identification of miRNA modulators to PARP inhibitor response |
| Q34038964 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions |
| Q34615545 | Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers |
| Q28511622 | Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification |
| Q24596134 | Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1 |
| Q61052110 | Identifying Modifiers of Tamoxifen Sensitivity Using High-Throughput Genetic and Chemical Screens |
| Q53007192 | Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. |
| Q38586809 | Inherited cylindromas: lessons from a rare tumour |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q27851474 | Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers |
| Q28475254 | Integrated functional, gene expression and genomic analysis for the identification of cancer targets |
| Q39207741 | Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies |
| Q33780945 | Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets |
| Q36300580 | Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study |
| Q22010135 | Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals |
| Q40310878 | Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment |
| Q44447339 | Intestinal renin-angiotensin system is stimulated after deletion of Lkb1. |
| Q53170046 | Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. |
| Q53182487 | Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. |
| Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
| Q40944633 | JNK activation is not required for Fas-mediated apoptosis |
| Q37165210 | LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest |
| Q34548473 | LKB1 kinase: master and commander of metabolism and polarity |
| Q36713548 | Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q49010210 | Linkage mapping of murine homolog of the yeast SPT6 gene to MMU11B1. |
| Q33402481 | Lkb1 deficiency alters goblet and paneth cell differentiation in the small intestine |
| Q28592491 | Lkb1 deficiency causes prostate neoplasia in the mouse |
| Q44606345 | Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? |
| Q21999790 | MAP kinase phosphatases |
| Q63383819 | MESH: Phase II trial of methotrexate as a synthetic lethal therapy for metastatic MSH2-deficient colorectal and other tumors |
| Q33883578 | MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases |
| Q37779240 | Making the best of PARP inhibitors in ovarian cancer |
| Q28395267 | Male breast cancer, age and sex chromosome aneuploidy |
| Q38613413 | Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer |
| Q38291864 | Mapping of two zinc finger protein genes to mouse chromosomes 4 and 7. |
| Q36922920 | Mechanisms of disease: angiogenesis and the management of breast cancer |
| Q38160737 | Mechanisms of resistance to therapies targeting BRCA-mutant cancers |
| Q37203133 | Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? |
| Q33521938 | Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q34820314 | Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement |
| Q41896118 | Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy |
| Q42463242 | Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma |
| Q37696965 | Mismatch repair deficient colorectal cancer in the era of personalized treatment |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q39006395 | Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast Cancer |
| Q45990996 | Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. |
| Q52428057 | Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. |
| Q34094563 | Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas |
| Q24319662 | Molecular cloning and functional characterization of a novel mitogen-activated protein kinase phosphatase, MKP-4 |
| Q46600448 | Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas |
| Q35906338 | Molecular response to aromatase inhibitor treatment in primary breast cancer |
| Q28388006 | Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer |
| Q42476596 | Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q41665683 | NLK is a novel therapeutic target for PTEN deficient tumour cells |
| Q24681926 | Neuregulin3 alters cell fate in the epidermis and mammary gland |
| Q73738890 | New biology of the oestrogen receptor |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q40108755 | Noninvasive detection of HER2 amplification with plasma DNA digital PCR. |
| Q39006292 | Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study |
| Q36014392 | Oncocytic change in pleomorphic adenoma: molecular evidence in support of an origin in neoplastic cells |
| Q41627000 | Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway |
| Q37039138 | Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. |
| Q36908116 | Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells |
| Q63383815 | P1-06-22: Identification of Biomarkers in Breast Cancer for Prediction of Response to PARP Inhibitor Olaparib |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q63383798 | PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer |
| Q38785588 | PARP inhibitor combination therapy |
| Q39182835 | PARP inhibitors: Synthetic lethality in the clinic |
| Q61867708 | PD-0017 * DRUGGABLE GENETIC DEPENDENCIES FOR MOLECULARLY DEFINED SUBGROUPS OF OESOPHAGEAL CANCER IDENTIFIED FROM HIGH-THROUGHPUT FUNCTIONAL PROFILING |
| Q43027152 | PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study |
| Q39871749 | PPM1D is a potential therapeutic target in ovarian clear cell carcinomas |
| Q39644716 | PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors |
| Q39142753 | Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer |
| Q33381821 | Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization |
| Q39606779 | Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers |
| Q46438773 | Patchy fur, a mouse coat mutation associated with X-Y nondisjunction, maps to the pseudoautosomal boundary region |
| Q42056082 | Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors |
| Q63383838 | Phenotypic effects of heterozygosity for a BRCA2 mutation |
| Q57713552 | Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity |
| Q39712677 | Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval |
| Q37555606 | Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency |
| Q63383821 | Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q37018385 | Pregnancy and the risk of breast cancer |
| Q37208782 | Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells |
| Q73704205 | Profiling familial breast cancer |
| Q37096858 | Psychological stress, adverse life events and breast cancer incidence: a cohort investigation in 106,000 women in the United Kingdom |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q33397910 | RNA interference screening demystified |
| Q24792463 | Receptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cells |
| Q57944702 | Reelin as a candidate gene for schizophrenia |
| Q28189311 | Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1 |
| Q36465333 | Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers |
| Q62583506 | Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study" |
| Q59291360 | Reproducibility of Estradiol and Testosterone Levels in Postmenopausal Women Over 5 Years: Results From the Breakthrough Generations Study |
| Q28268169 | Resistance to therapy caused by intragenic deletion in BRCA2 |
| Q57452824 | Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study" |
| Q62583500 | Response to ‘Comment on ‘Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study” |
| Q24803346 | Retroviral vectors for establishing tetracycline-regulated gene expression in an otherwise recalcitrant cell line |
| Q37831537 | Searching for synthetic lethality in cancer |
| Q58053593 | Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor |
| Q59291440 | Secular trends in age at menarche in women in the UK born 1908-93: results from the Breakthrough Generations Study |
| Q35930608 | Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer |
| Q35934208 | Sequence of cDNA for Xenopus XZFY-1 |
| Q33255332 | Signalling pathways implicated in early mammary gland morphogenesis and breast cancer |
| Q47162371 | Smoking and risk of breast cancer in the Generations Study cohort |
| Q35605452 | Stem cells and breast cancer: A field in transit |
| Q44147639 | Structural analysis of the chicken BRCA2 gene facilitates identification of functional domains and disease causing mutations |
| Q24315745 | Structural basis for recruitment of BRCA2 by PALB2 |
| Q40980465 | Structural basis for recruitment of BRCA2 by PALB2. |
| Q33606576 | Structural variation of the pseudoautosomal region between and within inbred mouse strains. |
| Q48010054 | Structure and chromosomal mapping of the TNF-alpha inducible endothelial protein 1 (Edp1) gene in the mouse |
| Q36042686 | Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma |
| Q28276782 | Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib |
| Q37801265 | Synthetic lethal approaches to breast cancer therapy |
| Q36042091 | Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors |
| Q57165496 | Synthetic lethal therapies for cancer: what's next after PARP inhibitors? |
| Q38262230 | Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors |
| Q36379543 | Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells |
| Q35051154 | Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations |
| Q38063790 | Tankyrase-targeted therapeutics: expanding opportunities in the PARP family |
| Q37222838 | Targeted therapy for cancer using PARP inhibitors |
| Q54062885 | Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. |
| Q57172993 | Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial |
| Q39335656 | Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers |
| Q27860519 | Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy |
| Q36162913 | Targeting the DNA repair defect of BRCA tumours |
| Q36561403 | Targeting the double-strand DNA break repair pathway as a therapeutic strategy |
| Q44903190 | Temporal stability and determinants of white blood cell DNA methylation in the breakthrough generations study |
| Q34413944 | The BRC repeats are conserved in mammalian BRCA2 proteins |
| Q35263089 | The Breakthrough Generations Study: design of a long-term UK cohort study to investigate breast cancer aetiology |
| Q37977004 | The DNA damage response and cancer therapy |
| Q34057978 | The Sry-related HMG box-containing gene Sox6 is expressed in the adult testis and developing nervous system of the mouse |
| Q41614439 | The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling |
| Q71762901 | The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases |
| Q35012807 | The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis |
| Q34389892 | The genomic landscape of oesophagogastric junctional adenocarcinoma |
| Q38360582 | The genomic profile of HER2-amplified breast cancers: the influence of ER status |
| Q28258565 | The human FXY gene is located within Xp22.3: implications for evolution of the mammalian X chromosome |
| Q112563426 | The mechanisms of catalysis and ligand binding for the SARS-CoV-2 NSP3 macrodomain from neutron and x-ray diffraction at room temperature |
| Q28267128 | The mitogen-activated protein kinase phosphatase-3 N-terminal noncatalytic region is responsible for tight substrate binding and enzymatic specificity |
| Q38292716 | The mouse Ftzf1 gene required for gonadal and adrenal development maps to mouse chromosome 2. |
| Q28593509 | The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase |
| Q37983690 | The potential of exploiting DNA-repair defects for optimizing lung cancer treatment |
| Q54472019 | The promise of combining inhibition of PI3K and PARP as cancer therapy. |
| Q63383832 | The proteasome is involved in determining differential utilization of double-strand break repair pathways |
| Q42213216 | The relationship between obesity and exposure to light at night: cross-sectional analyses of over 100,000 women in the Breakthrough Generations Study |
| Q24319910 | The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module |
| Q72315441 | The threonine residues in MAP kinase kinase 1 phosphorylated by MAP kinase in vitro are also phosphorylated in nerve growth factor-stimulated rat phaeochromocytoma (PC12) cells |
| Q37786127 | Therapeutic targeting of the DNA mismatch repair pathway |
| Q39868704 | Tiling path genomic profiling of grade 3 invasive ductal breast cancers |
| Q37690092 | Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study |
| Q52202109 | Transgenic mice carrying an Xist-containing YAC. |
| Q43892121 | Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression |
| Q37686415 | Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial |
| Q34111461 | Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction |
| Q28586360 | Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation |
| Q34439389 | Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C. |
| Q34489686 | Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization |
| Q36864047 | Utilizing RNA interference to enhance cancer drug discovery |
| Q39358611 | Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor |
| Q34241728 | Whole genome sequencing of matched primary and metastatic acral melanomas |
| Q41404014 | Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours |
| Q38335123 | X-chromosome inactivation may explain the difference in viability of XO humans and mice |
| Q52602645 | X-chromosome inactivation: X marks the spot for BRCA1. |
| Q37340680 | X-linked microtubule-associated protein, Mid1, regulates axon development |
| Q33919720 | Zfa is an expressed retroposon derived from an alternative transcript of the Zfx gene |
| Q48078825 | Zfp30, a KRAB domain containing zinc finger protein gene, maps to mouse chromosome 7. |
| Q36986691 | Zinc finger protein genes in the mouse genome |
| Q58438199 | [29] Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf |
| Q40344795 | p53 modulates homologous recombination by transcriptional regulation of the RAD51 gene |
| Q5363014 | Elizabeth Iorns | doctoral advisor | P184 |
| Q50384813 | Basser Global Prize | winner | P1346 |
| Alan Ashworth | wikipedia |
Search more.